Date: 2017-09-13
Type of information: Series B financing round
Company: Genenta Science (Italy)
Investors: Italian, British, and Swiss private investors, family offices, business angels, Banca Esperia (Italy) Mediolanum (Italy), board members
Amount: $8,4 Million (€7 Million)
Funding type: series B financing round
Planned used:
Others:
- • On September 13, 2017. Genenta Science, a biotech company committed to the development and commercialization of a hematopoietic stem cell gene therapy for tumors treatment, announced the closing of a $8 million (€7 million) series B financing. The Round was led by Italian, British, and Swiss private investors, family offices, and business angels, Series A investors and Board Members. The offering was oversubscribed. The total amount raised in two Rounds is equal to $20,4 Million (€17 Million).
- Guido Guidi, M.D. was appointed as a Board Member. Dr. Guidi served as Head of Pharma Region Europe and previously as Head of Oncology Europe at Novartis where he developed and launched several blockbuster products: Cosentyx, Entresto, Lucentis, Gilenya, Xolair, Ultibro, Seebri, Galvus, Exforge, Zometa, Femara e Glivec. He was also a member of the Novartis Pharma Executive Committee (PEC) and Chairman of the Novartis European Executive Committee.
- Prof. Kenneth C. Anderson is now part of the Scientific Advisory Board led by prof. Luigi Naldini, Genenta’s co-founder. Prof. Anderson directs the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at DanaFaberCancer Institute. And he is the Kraft Family Professor of Medicine at Harvard Medical School and the President Elect of ASH - American Society of Hematology.Genenta landed at Alexandria LaunchLabs®, the New York City’s premier startup platform located at the Alexandria Center® for Life Science, with the aim to explore the US market.
Therapeutic area: Cancer - Oncology
Is general: Yes
